Dermatology practical & conceptual · 2025
Bullous Pemphigoid and Epidemiological Patterns in Northern Greece: Insights from an 8-Year Observational Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Daponte Athina-Ioanna, Kalloniati Evangelia, Meltzanidou Parthena, Giannouli Maria, Tsitlakidou Anastasia, Oflidou Valentina, Boziou Maria, Kyriakou Aikaterini, Charalampidis Stylianos, Fotiadou Christina, Giannakou Anastasia, Lambropoulos Alexandros, Trigoni Anastasia, Trakatelli Myrto-Georgia, Apalla Zoe, Lazaridou Elizabeth, Patsatsi Aikaterini
Аннотация
INTRODUCTION: Bullous pemphigoid (BP) is an autoimmune disorder causing tense blisters on the skin and sometimes mucous membranes, primarily affecting older adults. It results from autoantibodies attacking the epidermal basement membrane. The incidence of BP is rising globally, particularly due to drug-induced cases.
OBJECTIVES: This study aimed to present epidemiological data on BP patients, response to systemic corticosteroid therapy, relapse rates, need for additional therapy, and overall prognosis.
METHODS: This retrospective study included patients diagnosed with BP and admitted to the Dermatology Department of a referral center in northern Greece from 2014 to 2022. The registry included parameters such as sex, age at onset, comorbidities, drug associations, hospitalization, additional immunosuppressive therapy or doxycycline use, time to tapering, and number of relapses.
RESULTS: Among the 188 patients (88 females, 100 males; mean age 76 years), 97% received systemic corticosteroid therapy, while 1.6% were treated with potent topical steroids alone. Doxycycline was administered to 8% of patients, and 11.7% received additional immunosuppressive agents. The most common comorbidity was diabetes mellitus (60.6%). BP was associated with gliptin intake in 36% of cases. Hospitalization was required for 79% of patients with corticosteroid tapering initiated on average by day twenty-three. Disease recurrence occurred in 34% of cases.
CONCLUSION: The high incidence rates in older adults and DPP-4 inhibitor users underscore the need for continued vigilance and research. Systemic corticosteroids remain the primary treatment at our center. Continuous monitoring and refinement of prevention and management strategies are crucial for effectively addressing BP.
OBJECTIVES: This study aimed to present epidemiological data on BP patients, response to systemic corticosteroid therapy, relapse rates, need for additional therapy, and overall prognosis.
METHODS: This retrospective study included patients diagnosed with BP and admitted to the Dermatology Department of a referral center in northern Greece from 2014 to 2022. The registry included parameters such as sex, age at onset, comorbidities, drug associations, hospitalization, additional immunosuppressive therapy or doxycycline use, time to tapering, and number of relapses.
RESULTS: Among the 188 patients (88 females, 100 males; mean age 76 years), 97% received systemic corticosteroid therapy, while 1.6% were treated with potent topical steroids alone. Doxycycline was administered to 8% of patients, and 11.7% received additional immunosuppressive agents. The most common comorbidity was diabetes mellitus (60.6%). BP was associated with gliptin intake in 36% of cases. Hospitalization was required for 79% of patients with corticosteroid tapering initiated on average by day twenty-three. Disease recurrence occurred in 34% of cases.
CONCLUSION: The high incidence rates in older adults and DPP-4 inhibitor users underscore the need for continued vigilance and research. Systemic corticosteroids remain the primary treatment at our center. Continuous monitoring and refinement of prevention and management strategies are crucial for effectively addressing BP.